VIVREON BIOSCIENCES LLC
- SAN DIEGO, CA 92121-4740
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
VIVREON BIOSCIENCES LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About VIVREON BIOSCIENCES LLC
- Headquarters
- SAN DIEGO, CA 92121-4740
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIP935LHN98ZV9
- CAGE75X47
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 19 awards
- Total awarded
- $19,702,937
- By phase
- SBIR Phase I: 11
- SBIR Phase II: 8
- By agency
- Department of Health and Human Services: 19
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2024: 3
- 2023: 2
- 2022: 4
- 2021: 1
- 2020: 1
- 2019: 3
- 2018: 1
- 2017: 2
- 2016: 1
Awards (most recent first)
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,996,385
Jul 1, 2025 – Mar 31, 2027
- Active
- Ends Mar 2027
Solicitation PAR23-219 (2023) · Topic NIA
Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $306,872
Sep 1, 2024 – Jul 31, 2025
Solicitation PA23-230 (2023) · Topic NIAMS
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,999,994
Aug 1, 2024 – Jul 31, 2026
Solicitation PA23-230 (2023) · Topic NIAID
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,499,594
Jul 1, 2024 – Jun 30, 2026
Solicitation DA23-021 (2023) · Topic NIDA
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $319,991
Jul 15, 2023 – Jun 30, 2024
Solicitation DA23-021 (2022) · Topic NIDA
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $352,030
Apr 15, 2023 – Mar 31, 2024
Solicitation PA21-259 (2021) · Topic NHLBI
Development of a Novel CRAC Channel Therapeutic for the Treatment of Primary Hyperhidrosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $245,256
Sep 15, 2022 – Jun 30, 2023
Solicitation PA21-259 (2021) · Topic NIAMS
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,549,974
Sep 15, 2022 – May 31, 2024
Solicitation PA20-272 (2020) · Topic NIA
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,873,040
Jun 1, 2022 – Nov 30, 2024
Solicitation PA21-259 (2021) · Topic 102
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $299,989
May 1, 2022 – Apr 30, 2023
Solicitation PA21-259 (2021) · Topic NIAID
Predevelopment of VV8321, a Novel CRAC Channel Therapeutic for the Treatment of Osteoarthritis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $252,039
Sep 22, 2021 – Mar 31, 2022
Solicitation PA20-260 (2020) · Topic NIAMS
Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $404,967
Sep 1, 2020 – Aug 31, 2022
Solicitation PA19-029 (2019) · Topic NIDA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,478,784
Sep 1, 2019 – Jan 31, 2021
Solicitation PA18-574 (2018) · Topic NCI
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $270,902
Aug 1, 2019 – Jul 31, 2020
Solicitation PAS18-187 (2018) · Topic Y
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,693,391
Jun 15, 2019 – May 31, 2022
Solicitation PA20-272 (2018) · Topic NIA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $225,000
Mar 2, 2018 – Mar 1, 2019
Solicitation PA17-302 (2017) · Topic 102
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,492,301
Aug 1, 2017 – May 31, 2019
Solicitation PA16-091 (2016) · Topic NIA
Predevelopment of VV a Novel CRAC Channel Inhibitor for the Treatment of Ulcerative Colitis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $219,975
Jul 1, 2017 – Jun 30, 2018
Solicitation PA16-302 (2016) · Topic R
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $222,453
Sep 30, 2016 – May 31, 2017
Solicitation PA16-091 (2019) · Topic NIA
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with VIVREON BIOSCIENCES LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.